Cellular immunotherapy for haematological malignancies: A pilot study of allogeneic mesenchymal stromal cells in myelodysplastic syndrome

Melita Cirillo

doi:10.26182/nnhf-c092

Cellular immunotherapy for haematological malignancies: A pilot study of allogeneic mesenchymal stromal cells in myelodysplastic syndrome

Melita Cirillo

UWA Medical School

Research output: Thesis › Master's Thesis

69 Downloads (Pure)

Abstract

Myelodysplastic syndrome (MDS) is a disorder of bone marrow failure presenting with anaemia, recurrent infections and bleeding. In patients with early stage MDS, standard care is supportive. Allogeneic mesenchymal stromal cell infusion represents a novel approach to immunotherapy in MDS. We utilise a TGA-licensed MSC product with established safety. This manuscript presents findings of phase 1 safety study administering allogeneic MSC to patients with early-stage MDS. The study has met its primary safety endpoint for MSC infusions in 5 patients. This study has demonstrated first-in-man safety of MSC infusion in MDS. Further studies are needed to assess dose and efficacy.

Original language	English
Qualification	Masters
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Sturm, Marian, Supervisor Pixley, Fiona, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	9 Nov 2022
DOIs	https://doi.org/10.26182/nnhf-c092
Publication status	Unpublished - 2022

Access to Document

10.26182/nnhf-c092

THESIS - MASTER BY RESEARCH - CIRILLO Melita - 2022
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cite this

@mastersthesis{b4baade1b8ad45fc912cd975ff56a3c4,

title = "Cellular immunotherapy for haematological malignancies: A pilot study of allogeneic mesenchymal stromal cells in myelodysplastic syndrome",

abstract = "Myelodysplastic syndrome (MDS) is a disorder of bone marrow failure presenting with anaemia, recurrent infections and bleeding. In patients with early stage MDS, standard care is supportive. Allogeneic mesenchymal stromal cell infusion represents a novel approach to immunotherapy in MDS. We utilise a TGA-licensed MSC product with established safety. This manuscript presents findings of phase 1 safety study administering allogeneic MSC to patients with early-stage MDS. The study has met its primary safety endpoint for MSC infusions in 5 patients. This study has demonstrated first-in-man safety of MSC infusion in MDS. Further studies are needed to assess dose and efficacy.",

keywords = "myelodysplasia, mesenchymal stromal cells, immunothearpy, leukaemia, cellular therapy",

author = "Melita Cirillo",

year = "2022",

doi = "10.26182/nnhf-c092",

language = "English",

school = "The University of Western Australia",

}

TY - THES

T1 - Cellular immunotherapy for haematological malignancies: A pilot study of allogeneic mesenchymal stromal cells in myelodysplastic syndrome

AU - Cirillo, Melita

PY - 2022

Y1 - 2022

N2 - Myelodysplastic syndrome (MDS) is a disorder of bone marrow failure presenting with anaemia, recurrent infections and bleeding. In patients with early stage MDS, standard care is supportive. Allogeneic mesenchymal stromal cell infusion represents a novel approach to immunotherapy in MDS. We utilise a TGA-licensed MSC product with established safety. This manuscript presents findings of phase 1 safety study administering allogeneic MSC to patients with early-stage MDS. The study has met its primary safety endpoint for MSC infusions in 5 patients. This study has demonstrated first-in-man safety of MSC infusion in MDS. Further studies are needed to assess dose and efficacy.

AB - Myelodysplastic syndrome (MDS) is a disorder of bone marrow failure presenting with anaemia, recurrent infections and bleeding. In patients with early stage MDS, standard care is supportive. Allogeneic mesenchymal stromal cell infusion represents a novel approach to immunotherapy in MDS. We utilise a TGA-licensed MSC product with established safety. This manuscript presents findings of phase 1 safety study administering allogeneic MSC to patients with early-stage MDS. The study has met its primary safety endpoint for MSC infusions in 5 patients. This study has demonstrated first-in-man safety of MSC infusion in MDS. Further studies are needed to assess dose and efficacy.

KW - myelodysplasia

KW - mesenchymal stromal cells

KW - immunothearpy

KW - leukaemia

KW - cellular therapy

U2 - 10.26182/nnhf-c092

DO - 10.26182/nnhf-c092

M3 - Master's Thesis

ER -

Cellular immunotherapy for haematological malignancies: A pilot study of allogeneic mesenchymal stromal cells in myelodysplastic syndrome

Abstract

Access to Document

Fingerprint

Cite this